Topic Hub

Longevity Rx — Head-to-Head Comparisons

10 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.

10articles

78keywords mapped

2026-05-26latest review

Explore

Longevity Rx — Head-to-Head Comparisons library

Showing 10 of 10 clinical reviews.

Access2026-05-26

NMN/NR vs Low-Dose Naltrexone: Cost and Access Compared

A head-to-head comparison of NMN/NR (nicotinamide mononucleotide/riboside) and low-dose naltrexone on price, insurance coverage, pharmacy access, and regulatory status for longevity-focused patients.

Read clinical review

Comparisons2026-05-26

NMN/NR vs Low-Dose Naltrexone: Head-to-Head Efficacy for Longevity

A clinical comparison of NMN/NR (nicotinamide mononucleotide/riboside) and low-dose naltrexone (LDN) for longevity, covering mechanisms, trial data, dosing, safety, and when each agent fits best.

Read clinical review

Safety2026-05-25

NMN/NR vs Low-Dose Naltrexone: Side-Effect Profile Head-to-Head

A clinical comparison of the side-effect profiles of nicotinamide mononucleotide/riboside (NMN/NR) and low-dose naltrexone (LDN), covering GI tolerance, sleep disruption, hepatic safety, and long-term risk data.

Read clinical review

Comparisons2026-05-27

NMN/NR vs Low-Dose Naltrexone: Switching Between Them

A clinical comparison of NMN/NR (nicotinamide mononucleotide/riboside) and low-dose naltrexone for longevity, including when and how to switch between them safely.

Read clinical review

Access2026-05-25

Rapamycin (Sirolimus) vs Low-Dose Naltrexone: Cost and Access Head-to-Head

A clinical comparison of rapamycin (sirolimus) and low-dose naltrexone (LDN) for longevity, covering pricing, prescribing access, insurance coverage, evidence base, and practical switching guidance.

Read clinical review

Comparisons2026-05-25

Rapamycin (Sirolimus) vs Low-Dose Naltrexone: Switching Between Them

Evidence-based comparison of rapamycin (sirolimus) and low-dose naltrexone (LDN) for longevity, including when and how to switch between them safely.

Read clinical review

Access2026-05-26

Rapamycin (Sirolimus) vs NMN/NR: Cost and Access Head-to-Head Comparison

A clinical comparison of rapamycin (sirolimus) and NMN/NR (nicotinamide mononucleotide/riboside) covering cost, access, insurance coverage, evidence quality, and practical prescribing considerations for longevity medicine.

Read clinical review

Comparisons2026-05-25

Rapamycin (Sirolimus) vs NMN/NR: Head-to-Head Efficacy for Longevity

Evidence-based comparison of rapamycin (sirolimus) and NMN/NR (nicotinamide mononucleotide/riboside) for longevity, covering mechanism, clinical trial data, dosing, safety, and practical guidance.

Read clinical review

Safety2026-05-25

Rapamycin (Sirolimus) vs NMN/NR: Side-Effect Profile Head-to-Head

A clinical comparison of the side-effect profiles of rapamycin (sirolimus) and NMN/NR (nicotinamide mononucleotide/riboside) for longevity, including trial data, dosing considerations, and safety monitoring.

Read clinical review

Comparisons2026-05-26

Rapamycin (Sirolimus) vs NMN/NR: Switching Between Them

A clinical comparison of rapamycin (sirolimus) and NMN/NR (nicotinamide mononucleotide/riboside) for longevity, including when and how to switch between these interventions.

Read clinical review